The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended darolutamide, an oral androgen receptor inhibitor (ARi), plus ADT in combination with docetaxel
Nordic Life Science
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
NLS News
Lundbeck and Otsuka Pharmaceutical have announced that the FDA has determined that the supplementary New Drug Application (sNDA) for brexpiprazole for the use in the treatment of agitation associated with
Advertisement
The last patient has now been included in the ongoing clinical study with ACD440, the lead non-opioid drug candidate in the painless platform, which is being developed against peripheral neuropathic
Nordic Biomarker was recently named ‘Exporter of the Year 2022’ but the Umeå-based company says its journey has only just begun. The company has announced its vision to become a
Just before Christmas, the Norwegian company announced that it has received support from Oslo County of 1.950 million NOK. The funding will support optimization of the synthesis of our two
Contract development and manufacturing organizations (CDMOs) are emerging as global key players within the pharmaceutical industry, and their Nordic presence and offering will give the region both resilience and a
Healthcare stock indices enjoyed a decade-long growth-phase until and including 2017. IPOs within the sector, at arguably far too steep valuations, continued riding on this growth phase, peaking somewhat later
The startup company has completed a heavily oversubscribed fundraise. The new funds will be used initially to expand the company’s clinical trial program for its Dermalyser AI-driven support tool in Sweden
Advertisement
Modus Therapeutics has submitted a patent application claiming the use of sevuparin, its lead asset, for the treatment of kidney disease. The patent application is based on novel preclinical work
The U.S. Food and Drug Administration has granted the designation for the company’s personalized cancer therapy, EVX-01, in combination with KEYTRUDA. In December 2022, Evaxion received FDA approval to proceed
The company has raised an additional 10.6 million SEK to accelerate commercialization of its SiPore health and food supplement portfolio. “In the current climate, the rapid completion and oversubscription of this
The new science city in Reykjavik is set to attract growing companies, foreign investors and even more talent. Despite being one of the world’s smallest capitals, Reykjavik has an innovative
The partnership will include access to the scientific, clinical and drug development expertise of the Leukemia & Lymphoma Society (LLS) as well as a strategic capital equity investment from LLS
AlzeCure Pharma has chosen a candidate drug (CD) and started the preclinical development phase with the company’s preventive and disease-modifying candidate drug Alzstatin ACD680. ACD680 is being developed within AlzeCure’s
Partner Article from Arex Advisor
Sweden’s Presidency in the EU: What it Means for the Pharma Industry
For six months starting in January 2023 Sweden will hold the Presidency of the Council of the European Union. It is much more than an honorary role, encompassing an opportunity for Sweden to both set new guidelines and see to the implementation of important existing policies.
Drug and Device Development
Nordic Nanovector has provided an update on PARADIGME, its Phase 2b trial of Betalutin in 3rd-line relapsed and anti-CD20 refractory follicular lymphoma. Following a comprehensive review and independent data evaluation
Ultimovacs has announced the completed recruitment of 118 patients with pleural mesothelioma in the NIPU trial. NIPU is a randomized, multi-center phase II trial initiated and sponsored by Oslo University Hospital with support from
IRLAB Therapeutics has announced the results from the Phase IIb study of mesdopetam in people with Parkinson’s disease levodopa-induced dyskinesias (PD-LIDs). The primary endpoint, change in daily hours of ON-time
Ultimovacs has announced that cemiplimab (Libtayo) will be used as the PD-1 checkpoint inhibitor in combination with UV1 in the Phase II randomized LUNGVAC trial rather than pembrolizumab (Keytruda). The
Mendus has presented survival data based on the completed active study period and long-term follow-up to date from the ADVANCE II clinical trial at the American Society of Hematology Annual
Profile
One of Nobel Laureate David Julius’ greatest joys is when people in his lab show him exciting data and make their own discoveries, and as a scientist and educator his
What began as a project for Evelina Vågesjö’s doctoral thesis grew into groundbreaking drug candidates and delivery methods, followed not long afterwards, by a clinical-stage biopharmaceutical company. Fascinated by the
Massachusetts Institute of Technology (MIT) in the US has produced more than its share of engineers and computer scientists, but unlike many of his peers, alumnus Dr. Robert Langer, ScD,
In a new job
Per Alfredsson has been appointed new Chief Operating Officer of AstraZeneca AB. Per Alfredsson took over the role after Katarina Ageborg on January 9th. He will maintain his role as
SwedenBIO has appointed the co-founder and operational manager of Sprint Bioscience, Jessica Martinsson, as its new Director General. “With her entrepreneurial experience and co-founder of a life science company, SwedenBIO
Evaxion Biotech has announced that its new Chief Executive Officer (CEO) Per Norlén has joined the company on October 3rd. “With Per at the steering wheel, we expect to bring
Careers
Surviving an episode of cancer as a teenager set Lao Saal on a path to seek out better ways to detect, monitor and treat the deadly cells. That determination drove him to earn medical and doctoral degrees at Columbia
JOB ALERTS
Read the latest issue of our magazine!
No 04 2022 // Welcome to our 15th Nobel Prize issue! We have decided to return to an old tradition and publish this issue in November, just in time for the glittering Nobel festivities, when the whole world’s attention is drawn to the Nordic region. This year we also have two Nordic (!) Laureates within the field of life sciences, Swedish Svante Pääbo and Danish Morten Meldal.
In addition, we have spoken to Business Region Göteborg’s investment advisor Iris Öhrn, we have found out what’s behind Nordic Biomarker’s recent success and we take a closer look on the critical role of Nordic CDMOs. This issue also includes a commentary about recent trends in healthcare, a perspective about Real-World Data, and interviews with the new CEOs of Industrifonden and SwedenBIO.
This, and much more, in our latest issue – out now!
Venture Capital
Nordic Life Science asked Fredrik Dahl, co-founder at Colibri Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges Nordic life science
Nordic Life Science asked Claus Andersson, General Manager at Sunstone Life Science Venture, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
Nordic Life Science asked Inka Mero, Founder and Managing Partner at Voima Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
“Start by asking what the problem is that you are trying to solve and develop the technology, team, and plan to solve that problem – not what you can do with the technology.” – Fredrik Dahl, Colibri Ventures
Upcoming events
Meet your next strategic partner at Europe’s largest springtime partnering event. This year’s event will be arranged as an in-person event in Basel, Switzerland, March 20-22, and a digital event,
Swiss Nordic Bio is a high-level partnering and investor conference aimed at connecting healthcare innovations, investor and industry. The conference is the number one platform that gathers life science professionals
Meet decision makers at leading and upcoming drug discovery and technology companies from the UK and Nordic regions, and investment firms throughout Europe. Learn from major investment firms about the
As Precision Medicine initiatives around the world gather pace, the Nordic countries are in an enviable position when it comes to joining all the dots. The link between digital health,
The latest research news from the Nordic region
Science articles
Findings from the major study iStopMM has been used to redefine monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma. We spoke with Þórir Einarsson Long, one of
An international team of researchers have combined ideas from biology, computer science and mathematics to explain why evolution seems to favor symmetry. We spoke with Iain Johnston, a professor at
Thanks to a donation of SEK 35 million from financier and philanthropist Rune Andersson, Karolinska Institutet’s research group leader Andrea Carmine Belin will very soon be setting up the world’s
Olink Holding has announced the 2022 winner of the young researchers’ award, Novelties in Biomarkers, Maria Martin-Grau at the University of Valencia, Spain. Novelties in Biomarkers is an annual award
The European Patent Office (EPO) has honoured Hungarian-American researcher Katalin Karikó with the European Inventor Award 2022 in the category “Lifetime achievement”, for her seminal work in developing modified messenger
Dr Martin Oeggerli at Micronaut GmBH, Basel, Switzerland, is this year’s winner of the Lennart Nilsson Award. Martin Oeggerli holds a PhD in medical molecular biology. Since 2005, he works
Nordic Life Science
The latest clinical trials
The last patient has now been included in the ongoing clinical study with ACD440, the lead non-opioid drug candidate in the painless platform, which is being developed against peripheral neuropathic
Ultimovacs has announced the completed recruitment of 118 patients with pleural mesothelioma in the NIPU trial. NIPU is a randomized, multi-center phase II trial initiated and sponsored by Oslo University Hospital with support from
IRLAB Therapeutics has announced the results from the Phase IIb study of mesdopetam in people with Parkinson’s disease levodopa-induced dyskinesias (PD-LIDs). The primary endpoint, change in daily hours of ON-time
Ultimovacs has announced that cemiplimab (Libtayo) will be used as the PD-1 checkpoint inhibitor in combination with UV1 in the Phase II randomized LUNGVAC trial rather than pembrolizumab (Keytruda). The
Mendus has presented survival data based on the completed active study period and long-term follow-up to date from the ADVANCE II clinical trial at the American Society of Hematology Annual
IRLAB Therapeutics has announced that the final patient has completed the treatment period and follow-up visit in the Phase IIb study of mesdopetam in levodopa-induced dyskinesia in people with Parkinson’s
Spago Nanomedical has received regulatory approval to initiate a Phase IIa clinical study with its MRI contrast agent SN132D in endometriosis. Patient recruitment has started, and the first patient is
Evaxion Biotech has announced clinical data from the first-in-human study of its DNA-based cancer immunotherapy, EVX-02. In the clinical study, EVX-02 is given in combination with a checkpoint inhibitor and
EpiEndo Pharmaceuticals has received regulatory approval to commence a Phase 2a clinical trial with lead molecule EP395 in COPD (Chronic Obstructive Pulmonary Disease) patients. EP395 is an orally available macrolide
Sign up to our newsletter
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
Advertisement
